Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon

Executive Summary

Physicians more frequently prescribe Bristol-Myers Squibb's Orencia than Genentech/Biogen Idec's Rituxan for rheumatoid arthritis, Bristol Worldwide Pharmaceuticals President Lamberto Andreotti said

You may also be interested in...

Bristol Sprycel Clears FDA As First Second-Line Leukemia Agent

Bristol-Myers Squibb will be required to submit follow-up data from ongoing clinical trials to convert the accelerated approval of Sprycel for chronic myeloid leukemia to full approval, FDA said after clearing dasatinib June 28

Rituxan RA Approval Raises The Stakes, But With A Lower Price

Genentech/Biogen Idec are pricing Rituxan (rituximab) for rheumatoid arthritis at a lower cost for most patients than the closest comparable biologic, Bristol-Myers Squibb's Orencia (abatacept)

Bristol Will Use One Distributor To Ensure Patient Access For Orencia Launch

Bristol-Myers Squibb is launching its rheumatoid arthritis treatment Orencia (abatacept) through a sole distributor to ensure patient access while the firm works to expand its manufacturing capacity

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts